NHS England considers the commissioning of medicines for rare diseases as they would any treatment for any condition. The process for developing clinical policies for treatments is published on the NHS England website:
In addition, NHS England recently undertook a consultation on the process for prioritising treatments that required investment, and the response to that consultation is published here:
A recent consultation exercise has also been undertaken to consider NHS England’s ‘generic policies’ that consider decision making of treatments outside the annual investment prioritisation process. The outcome of that consultation will be published at a later date once the responses have been fully considered.